About AsclepiX Therapeutics
AsclepiX Therapeutics is a private company based in Bethesda, Maryland, incorporated in 2023 in Delaware. It has reported $27,954,998 raised in four offerings on Form D since February 2017. Its chief executive is Robert Dempsey.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jul 19, 2023 | Apr 26, 2024 | $10,044,498of $12.5M target | 9 | $1.1M | EquityRule 506(b) | Form D ↗ |
| May 27, 2020 | Jun 11, 2020 | $10,000,000of $35.0M target | 34 | $294K | EquityRule 506(b) | Form D ↗ |
| Oct 12, 2018 | Oct 25, 2018amended Jun 17, 2019 | $7,735,500of $10.0M target | 26 | $297K | Debt, Options, Securities on exerciseRule 506(b) | Form D/A ↗1 earlier filing |
| Feb 3, 2017 | Feb 9, 2017 | $175,000of $1.0M target | 5 | $35,000 | Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Total, four offerings | $27,954,998 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on AsclepiX Therapeutics's Form D filed Apr 26, 2024.
RD
Robert Dempsey
Chief Executive Officer
BA
Ben Askew
Director
JB
Josh Barer
Director
CG
Chris Garabedian
Director
AP
Aleksander Popel
Executive officer
SS
Sapna Srivastava
Director
AS
Amir Shojaei
Executive officer
NP
Niranjan Pandey
Executive officer
JT
Jill Tierney
Executive officer
JG
Jordan Green
Director
Earlier filings also listed Kevin Slawin, MD (executive officer and director, last listed Jun 2020), Joshua Barer (director, last listed Jun 2020) and Wendy Perrow (chief executive officer and director, last listed Jun 2019).